Drugs / AHB-137
Trials 12 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07600788 | May 2026 → May 2028 expected | chronic hepatitis B virus infection | Ausper Biopharma Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT05717686 | Feb 2023 → Jan 2025 | chronic hepatitis B virus infection | AusperBio Therapeutics Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06115993 | Aug 2023 → Dec 2024 | chronic hepatitis B virus infection | Ausper Biopharma Co., Ltd. | Completed | No outcome recorded |
| Phase 28 trials | ||||||
| Phase 2 | NCT07635186 | Jun 2026 → Jun 2027 expected | chronic hepatitis B virus infection | Ausper Biopharma Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07654283 | Jun 2026 → Mar 2027 expected | chronic hepatitis B virus infection | AusperBio Therapeutics Inc. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07370207 | Mar 2026 → Dec 2028 expected | chronic hepatitis B virus infection | AusperBio Therapeutics Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT07137910 | Sep 2025 → Dec 2026 expected | chronic hepatitis B virus infection | Ausper Biopharma Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT06993480 | Jul 2025 → Jul 2026 overdue | chronic hepatitis B virus infection | Ausper Biopharma Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT07069569 | Jun 2025 → Jul 2027 expected | chronic hepatitis B virus infection | Ausper Biopharma Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT06829329 | Dec 2024 → Aug 2026 overdue | chronic hepatitis B virus infection | Ausper Biopharma Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06550128 | Jul 2024 → May 2025 overdue | chronic hepatitis B virus infection | Ausper Biopharma Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07246889 | Aug 2025 → Dec 2026 expected | chronic hepatitis B virus infection | Ausper Biopharma Co., Ltd. | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 13 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AHB-137 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07654283 ↗ |
| Modality | Antisense oligonucleotide | “AHB-137 is a novel antisense oligonucleotide targeting a conserved 3'-terminal region of HBV mRNA.” PMID 42176239 ↗ May 2026 |
| Route | Subcutaneous | “by subcutaneous (SC) injection” NCT05717686 ↗ |